Kiniksa Pharmaceuticals International, plc Income Statement
KNSA / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
Kiniksa Pharmaceuticals International, plc reported $678M in revenue and $59M in net income for FY2025. Revenue has grown at a 104.8% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M | - | - | - | - |
| Cost of Revenue | $77.7M | $60.9M | $33.4M | $22.9M | $9.1M | - | - | - | - |
| SG&A Expense | $196.3M | $168.0M | $129.4M | $98.0M | $35.0M | $45.3M | $35.0M | $21.6M | $9.0M |
| R&D Expense | $96.9M | $111.6M | $76.1M | $65.5M | $135.0M | $112.0M | $135.0M | $86.6M | $56.4M |
| Operating Income | $77.2M | -$45.6M | -$25.2M | $9.8M | -$170.0M | -$157.4M | -$170.0M | -$108.2M | -$65.4M |
| Income Tax | $29.9M | $7.0M | -$30.7M | -$172.3M | -$2.0M | $5.2M | -$2.0M | -$214.0K | $2.0K |
| Net Income | $59.0M | -$43.2M | $14.1M | $183.4M | -$161.9M | -$161.4M | -$161.9M | -$103.2M | -$64.9M |
| EPS (Basic) | $0.80 | -$0.60 | $0.20 | -$2.61 | -$2.99 | -$2.61 | -$2.99 | - | - |
| EPS (Diluted) | $0.75 | -$0.60 | $0.20 | -$2.61 | -$2.99 | -$2.61 | -$2.99 | - | - |
| Shares Outstanding | 79.0M | 71.4M | 71.9M | 61.8M | 54.0M | 61.8M | 54.0M | 29.5M | 1.8M |
| Operating Margin | 11.4% | -10.8% | -9.3% | 4.4% | -441.0% | - | - | - | - |
| Profit Margin | 8.7% | -10.2% | 5.2% | 83.3% | -419.9% | - | - | - | - |